Advertisement

Topics

Boehringer Ingelheim GmbH Company Profile

23:24 EDT 20th September 2017 | BioPortfolio

Boehringer Ingelheim is a research-driven group of companies dedicated to researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life.Our business consists of Prescription Medicines, Consumer Health Care and Animal Health. Activities grouped under Industrial Customer include Biopharmaceuticals and Chemicals.
We focus on the production of innovative drugs and treatments that represent major therapeutic advances.

Location

Binger Str. 173
Ingelheim
Ingelheim
55216
Germany

Contact

Phone: 49/6132/77 0
Fax: 49/6132/72 0
Email: info@boehringer-ingelheim.at


News Articles [553 Associated News Articles listed on BioPortfolio]

Boehringer Ingelheim GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Updated: 06052017] Prices from USD $350

Boehringer Ingelheim GmbH Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Boehringer Ingelheim GmbH Mergers Acquisitions MA, Partnerships Alliances and In...

Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs

Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand.  The new Phase I trials initi...

Boehringer Ingelheim mit gutem Wachstum im ersten Halbjahr 2017

Ingelheim (ots) - - Querverweis: Bildmaterial wird über obs versandt und ist abrufbar unter http://www.presseportal.de/bilder - Boehringer Ingelheim zieht eine positive Bilanz nach dem ersten Halbj.....

Boehringer Ingelheim’s adalimumab biosimilar ‘equivalent’ to Humira

Germany-based biologicals specialist Boehringer Ingelheim (Boehringer) announced on 14 June 2017 positive results from its pivotal phase III study of its candidate adalimumab biosimilar.

Boehringer Ingelheim initiates phase IIa study of liver disease NASH compound

Boehringer Ingelheim and pharmaceutical company Pharmaxis announce that Boehringer Ingelheim has initiated a European and North American phase IIa trial in NASH with BI 1467335 (formerly known as PX...

Boehringer Ingelheim Upping Manufacturing Capacity

NewsBoehringer Ingelheim breaks ground on $217 million expansion of Fremont, California manufacturing facility. Expansion will triple capacity, add nearly 300 new jobs.

Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at ADA

NewsWith compounds representing several of the largest diabetes treatment classes, Boehringer Ingelheim and Lilly will feature posters, abstracts and oral presentations for their range of products, in...

Boehringer Ingelheim achieves good growth in the first half of 2017

Boehringer Ingelheim has delivered positive results for the first half of 2017. Net sales increased by 24 per cent on the same period in the previous year to 9.2 billion euros after adjustment for cur...

Drugs and Medications [85 Associated Drugs and Medications listed on BioPortfolio]

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Zantac [Boehringer Ingelheim Pharmaceuticals, Inc.]

Zantac Drug Facts

Dulcolax balance [Boehringer Ingelheim Pharmaceuticals Inc]

Boehringer-Ingelheim Consumer Health Care Products Dulcolax Balance® Drug Facts

Pradaxa [Boehringer Ingelheim Pharmaceuticals Inc.]

These highlights do not include all the information needed to use PRADAXA safely and effectively. See full prescribing information for PRADAXA. PRADAXA® (dabigatran etexilate mesylate) capsules for o...

PubMed Articles [22 Associated PubMed Articles listed on BioPortfolio]

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

The interleukin-23 pathway is implicated genetically and biologically in the pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of risankizumab (BI 655066, Boehringer Ingelhei...

Evaluation of in-feed larch sawdust anti-inflammatory effect in sows.

The study aimed to investigate the possible anti-inflammatory activity of larch sawdust as feed supplement in lactating sows' diet and its possible effect on the prevalence of Postpartum Dysgalactia S...

Comparison of a commercially available oral nutritional supplement and intravenous fluid therapy for dehydration in dairy calves.

Calf scours is a primary cause of morbidity and mortality in the dairy industry. Effective treatments are needed to minimize death, maximize welfare, and maintain growth and productivity. The objectiv...

Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study.

To evaluate safety (primary objective) and efficacy of increasing doses (400 U up to 800 U) of incobotulinumtoxinA (Xeomin, Merz Pharmaceuticals GmbH) for patients with limb spasticity.

Biomechanical Characterization of Subclinical Keratoconus Without Topographic or Tomographic Abnormalities.

To present a case series of patients with subclinical keratoconus with normal topometric (anterior curvature) and tomographic findings in one eye who showed abnormalities detected by Corvis ST (Oculus...

Clinical Trials [49 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride

to evaluate the bioavailability of ambroxol hydrochloride soft pastilles (test formulation), manufactured by Bolder Arzneimittel GmbH & Co. KG to Boehringer Ingelheim compared to ambroxol ...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions

The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam tablets, 15 mg, to Mobic® Tablets, 15 mg (Boehringer Ingelheim) under fasting conditions using a sin...

Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition

The objective of this study is to determine the relative bioavailability of one 15 mg Meloxicam tablet (Dr. Reddy. Laboratories Ltd.,Generics) versus one 15 mg Mobic (meloxicam) Tablet (Bo...

Companies [556 Associated Companies listed on BioPortfolio]

Boehringer Ingelheim Pharma GmbH & Co. KG

Boehringer Ingelheim erforscht, entwickelt, produziert und vermarktet Arzneimittel für Menschen in aller Welt.Mit 37.406 Mitarbeitern, die in 143 Gesellschaften auf allen Kontinenten beschäftigt sin...

Boehringer Ingelheim Pharmaceuticals, Inc

Boehringer Ingelheim Corporation is the U.S. member of the Boehringer Ingelheim worldwide group of companies dedicated to the discovery, development, manufacture and marketing of innovative human and ...

Boehringer Ingelheim Limited

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146...

Boehringer Ingelheim Pharmaceuticals Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group ...

Boehringer Ingelheim Pharmaceuticals, Inc.

Metabolism is one of Boehringer Ingelheim's core R&D areas and diabetes is one of the indications at the center of interest within the company's global research network. Boehringer Ingelheim is commit...

More Information about "Boehringer Ingelheim GmbH" on BioPortfolio

We have published hundreds of Boehringer Ingelheim GmbH news stories on BioPortfolio along with dozens of Boehringer Ingelheim GmbH Clinical Trials and PubMed Articles about Boehringer Ingelheim GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Boehringer Ingelheim GmbH Companies in our database. You can also find out about relevant Boehringer Ingelheim GmbH Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record